Zkusit zdarma
Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc.

APGE
Cena:
$ 81.16
-1.27 (-1.54%)
Valuace
70
Růst
0
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Apogee Therapeutics: Targeting Atopic Dermatitis

Apogee Therapeutics: Targeting Atopic Dermatitis

11:53 21-05-2026

Apogee Therapeutics, Inc. has roughly doubled since October 2025, driven by promising data for the l...

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

7:00 11-05-2026

Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD...

Apogee Therapeutics (NASDAQ:APGE) Reaches New 1-Year High – Still a Buy?

Apogee Therapeutics (NASDAQ:APGE) Reaches New 1-Year High – Still a Buy?

2:19 15-04-2026

Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report)'s share price hit a new 52-week high on We...

Apogee Therapeutics (NASDAQ:APGE) CEO Sells $1,651,600.00 in Stock

Apogee Therapeutics (NASDAQ:APGE) CEO Sells $1,651,600.00 in Stock

4:04 13-04-2026

Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) CEO Michael Thomas Henderson sold 20,000 s...

Aberdeen Group plc Lowers Stake in Apogee Therapeutics Inc. $APGE

Aberdeen Group plc Lowers Stake in Apogee Therapeutics Inc. $APGE

3:08 10-04-2026

Aberdeen Group plc lessened its stake in Apogee Therapeutics Inc. (NASDAQ: APGE) by 34.1% during the...

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

16:01 26-03-2026

SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE...

Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors

Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors

11:33 26-03-2026

The CEO of Apogee Therapeutics reported selling 20,000 shares of the company for approximately $1.50...

Apogee Therapeutics (NASDAQ:APGE) Reaches New 52-Week High – Here’s Why

Apogee Therapeutics (NASDAQ:APGE) Reaches New 52-Week High – Here’s Why

4:48 26-03-2026

Shares of Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) hit a new 52-week high during mi...

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

21:53 24-03-2026

SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE...

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

11:31 24-03-2026

Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD cand...

Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone

Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone

10:54 24-03-2026

Apogee Therapeutics, Inc. maintains a Strong Buy rating following positive 52-week maintenance data ...

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript

17:33 23-03-2026

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to...

Apogee Therapeutics: Two Shots A Year, One Shot At Disruption

Apogee Therapeutics: Two Shots A Year, One Shot At Disruption

17:12 23-03-2026

Apogee Therapeutics (APGE) remains a Buy, supported by strong Phase 2 data for zumilokibart in atopi...

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

16:01 23-03-2026

SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE...

Apogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data Readout

Apogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data Readout

10:04 23-03-2026

The data revealed that zumilokibart demonstrated durable maintenance of response with both 3- and 6-...

How Apogee, Up 14%, Plans To Take On Rival Regeneron's Eczema Drug

How Apogee, Up 14%, Plans To Take On Rival Regeneron's Eczema Drug

9:59 23-03-2026

Apogee Therapeutics reported a "best case scenario" Monday for its potential rival to eczema drug, D...

Apogee Therapeutics to Participate in Upcoming March Conferences

Apogee Therapeutics to Participate in Upcoming March Conferences

7:30 24-02-2026

SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE)...

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction

13:56 22-02-2026

Perceptive Advisors increased its Apogee Therapeutics position by 978,662 shares; the estimated trad...

Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of “Moderate Buy” by Brokerages

Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of “Moderate Buy” by Brokerages

4:10 21-02-2026

Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) has been assigned a consensus rating of "M...

Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million

Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million

10:47 14-02-2026

Affinity Asset Advisors bought 61,500 shares of Apogee Therapeutics in the fourth quarter; the estim...

close

APOGEE THERAPEUTICS TO PARTICIPATE AT THE GUGGENHEIM EMERGING OUTLOOK: BIOTECH SUMMIT 2026

05-02-2026
SAN FRANCISCO AND BOSTON, FEB. 05, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE)...
Více zde

APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 1B TRIAL OF ZUMILOKIBART (APG777), ITS POTENTIALLY BEST-IN-CLASS ANTI-IL-13 ANTIBODY, IN PATIENTS WITH MILD-TO-MODERATE ASTHMA AND HIGHLIGHTS 2026 ANTICIPATED MILESTONES AND OUTLOOK

06-01-2026
PHASE 1B INTERIM RESULTS OF ZUMILOKIBART (APG777) IN ASTHMA DEMONSTRATED RAPID AND DURABLE SUPPRESSI...
Více zde

APOGEE THERAPEUTICS TO HOST CONFERENCE CALL TO REPORT INTERIM RESULTS FROM THE PHASE 1B TRIAL OF APG777 IN PATIENTS WITH MILD-TO-MODERATE ASTHMA AND 2026 ANTICIPATED MILESTONES ON JANUARY 6, 2026

05-01-2026
SAN FRANCISCO AND BOSTON, JAN. 05, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE)...
Více zde

APOGEE THERAPEUTICS PROVIDES PIPELINE PROGRESS AND REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

10-11-2025
PIPELINE PROGRAMS CONTINUE TO ADVANCE, WITH FOUR CLINICAL DATA READOUTS ANTICIPATED IN 2026; APG777 ...
Více zde

APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1 RESULTS FROM HEALTHY VOLUNTEER TRIAL OF APG333, ITS NOVEL HALF-LIFE EXTENDED TSLP ANTIBODY

10-11-2025
INTERIM PHASE 1 RESULTS FOR APG333 EXCEEDED TRIAL OBJECTIVES, DEMONSTRATED A HALF-LIFE OF APPROXIMAT...
Více zde

APOGEE THERAPEUTICS TO PARTICIPATE IN UPCOMING CONFERENCES

03-11-2025
SAN FRANCISCO AND BOSTON, NOV. 03, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE...
Více zde

APOGEE THERAPEUTICS, INC. ANNOUNCES CLOSING OF PUBLIC OFFERING AND FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES FOR GROSS PROCEEDS OF $345 MILLION

10-10-2025
SAN FRANCISCO AND BOSTON, OCT. 10, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE)...
Více zde

APOGEE THERAPEUTICS, INC. ANNOUNCES PRICING OF $300 MILLION UNDERWRITTEN PUBLIC OFFERING

08-10-2025
SAN FRANCISCO AND BOSTON, OCT. 08, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE)...
Více zde

APOGEE THERAPEUTICS, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING

08-10-2025
SAN FRANCISCO AND BOSTON, OCT. 08, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE)...
Více zde

APOGEE THERAPEUTICS ANNOUNCES LATE-BREAKER PRESENTATION OF 16-WEEK DATA FROM PHASE 2 APEX TRIAL OF APG777 FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS AT THE UPCOMING EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) 2025 CONGRESS

11-09-2025
SAN FRANCISCO AND BOSTON, SEPT. 11, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APG...
Více zde

APOGEE THERAPEUTICS TO PARTICIPATE AT THE STIFEL 2025 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM

03-09-2025
SAN FRANCISCO AND BOSTON, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APG...
Více zde

APOGEE THERAPEUTICS PROVIDES PIPELINE PROGRESS AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

11-08-2025
POSITIVE 16-WEEK DATA FROM APEX PHASE 2 PART A MET ALL PRIMARY AND KEY SECONDARY ENDPOINTS FOR APG77...
Více zde

APOGEE THERAPEUTICS ANNOUNCES POSITIVE 16-WEEK DATA FROM PHASE 2 APEX CLINICAL TRIAL OF APG777, ITS POTENTIALLY BEST-IN-CLASS ANTI-IL-13 ANTIBODY, IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

07-07-2025
APEX PART A MET ALL PRIMARY AND KEY SECONDARY ENDPOINTS AND EXCEEDED TRIAL OBJECTIVES, INCLUDING 7 1...
Více zde

APOGEE THERAPEUTICS TO HOST CONFERENCE CALL TO REPORT PART A 16-WEEK DATA FROM THE PHASE 2 APEX TRIAL OF APG777 IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS ON JULY 7, 2025

06-07-2025
SAN FRANCISCO AND BOSTON, JULY 06, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE...
Více zde

APOGEE THERAPEUTICS TO PARTICIPATE AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

29-05-2025
SAN FRANCISCO AND BOSTON, MAY 29, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE)...
Více zde

APOGEE THERAPEUTICS PROVIDES BUSINESS UPDATE, PIPELINE PROGRESS AND REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

12-05-2025
PHASE 2 APEX TRIAL OF APG777 IN ATOPIC DERMATITIS ADVANCING WITH INTERIM PART A 16-WEEK DATA EXPECTE...
Více zde

APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS FROM THE PHASE 1B TRIAL OF APG808, ITS NOVEL HALF-LIFE EXTENDED IL-4RΑ ANTIBODY, IN PATIENTS WITH MILD-TO-MODERATE ASTHMA

12-05-2025
MULTIPLE DOSES OF APG808 RESULTED IN RAPID SUPPRESSION OF FENO, A BIOMARKER OF TYPE 2 INFLAMMATION A...
Více zde

APOGEE THERAPEUTICS TO PARTICIPATE AT THE BANK OF AMERICA 2025 HEALTH CARE CONFERENCE

01-05-2025
SAN FRANCISCO AND BOSTON, MAY 01, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE)...
Více zde

APOGEE THERAPEUTICS PROVIDES PIPELINE PROGRESS AND REPORTS FULL YEAR 2024 FINANCIAL RESULTS

03-03-2025
ACCELERATED EXECUTION OF PHASE 2 APEX CLINICAL TRIAL FOR APG777, WITH PART A OVER-ENROLLED AND PART ...
Více zde

APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1 RESULTS FROM THE APG990 HEALTHY VOLUNTEER TRIAL, UNLOCKING POTENTIAL MAINTENANCE DOSING EVERY THREE AND SIX MONTHS FOR APG279 (APG777 + APG990)

03-03-2025
INTERIM PHASE 1 RESULTS FOR APG990, A NOVEL HALF-LIFE EXTENDED OX40L ANTIBODY, EXCEEDED TRIAL OBJECT...
Více zde

APOGEE THERAPEUTICS TO HOST CONFERENCE CALL TO REPORT INTERIM RESULTS FROM THE PHASE 1 HEALTHY VOLUNTEER TRIAL FOR APG990 AND PROVIDE COMBINATION STRATEGY UPDATE ON MARCH 3, 2025

28-02-2025
SAN FRANCISCO AND BOSTON, FEB. 28, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE...
Více zde

APOGEE THERAPEUTICS TO PARTICIPATE IN UPCOMING MARCH INVESTOR CONFERENCES

25-02-2025
SAN FRANCISCO AND BOSTON, FEB. 25, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE...
Více zde

APOGEE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PART B OF PHASE 2 APEX TRIAL OF APG777 IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

03-02-2025
ENROLLMENT OF PART A COMPLETED AHEAD OF SCHEDULE AND EXCEEDED ENROLLMENT TARGET WITH 123 PATIENTS EN...
Více zde

APOGEE THERAPEUTICS TO PARTICIPATE AT THE GUGGENHEIM SMID CAP BIOTECH CONFERENCE

29-01-2025
SAN FRANCISCO AND BOSTON, JAN. 29, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE...
Více zde

APOGEE THERAPEUTICS HIGHLIGHTS PROGRESS AND BEST-IN-CLASS POTENTIAL OF NOVEL BIOLOGIC PROGRAMS FOR I&I DISEASES AT 2024 INAUGURAL R&D DAY

02-12-2024
POSITIVE INTERIM PHASE 1 DATA INDICATE APG808 WAS WELL-TOLERATED WITH HALF-LIFE OF APPROXIMATELY 55 ...
Více zde

APOGEE THERAPEUTICS ANNOUNCES AGENDA FOR VIRTUAL R&D DAY

29-11-2024
SAN FRANCISCO AND WALTHAM, MASS., NOV. 29, 2024 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASD...
Více zde

APOGEE THERAPEUTICS TO HOST INAUGURAL VIRTUAL R&D DAY ON DECEMBER 2, 2024

18-11-2024
COMPANY TO HIGHLIGHT PROGRESS ACROSS ITS PIPELINE AND SHOWCASE ITS PATH TO RESHAPING THE STANDARD OF...
Více zde

APOGEE THERAPEUTICS TO PARTICIPATE IN UPCOMING NOVEMBER INVESTOR CONFERENCES

04-11-2024
SAN FRANCISCO AND WALTHAM, MASS., NOV. 04, 2024 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASD...
Více zde

APOGEE THERAPEUTICS ANNOUNCES POSTER PRESENTATION AT THE ACAAI 2024 ANNUAL SCIENTIFIC MEETING

16-10-2024
SAN FRANCISCO AND WALTHAM, MASS., OCT. 16, 2024 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASD...
Více zde

APOGEE THERAPEUTICS TO PARTICIPATE AT THE STIFEL 2024 IMMUNOLOGY AND INFLAMMATION SUMMIT

12-09-2024
SAN FRANCISCO AND WALTHAM, MASS., SEPT. 12, 2024 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NAS...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-06 00:00:008-KStáhnout
2025-11-10 00:00:008-KStáhnout
2025-11-10 00:00:0010-QStáhnout
2025-10-10 01:00:008-KStáhnout
2025-10-10 00:00:008-KStáhnout
2025-08-11 01:00:008-KStáhnout
2025-08-11 01:00:0010-QStáhnout
2025-08-11 00:00:008-KStáhnout
2025-08-11 00:00:0010-QStáhnout
2025-07-07 01:00:008-KStáhnout
2025-07-07 00:00:008-KStáhnout
2025-06-23 01:00:008-KStáhnout
2025-06-23 00:00:008-KStáhnout
2025-05-12 01:00:008-KStáhnout
2025-05-12 01:00:0010-QStáhnout
2025-05-12 00:00:008-KStáhnout
2025-05-12 00:00:0010-QStáhnout
2025-03-11 00:00:008-KStáhnout
2025-03-10 23:00:008-KStáhnout
2025-03-03 00:00:008-KStáhnout
2025-03-03 00:00:0010-KStáhnout
2025-03-02 23:00:008-KStáhnout
2025-03-02 23:00:0010-KStáhnout
2025-02-03 00:00:008-KStáhnout
2025-02-02 23:00:008-KStáhnout
2024-12-10 00:00:008-KStáhnout
2024-12-09 23:00:008-KStáhnout
2024-12-02 00:00:008-KStáhnout
2024-12-01 23:00:008-KStáhnout
2024-11-12 00:00:008-KStáhnout
2024-11-12 00:00:0010-QStáhnout
2024-11-11 23:00:008-KStáhnout
2024-11-11 23:00:0010-QStáhnout
2024-10-24 01:00:008-KStáhnout
2024-10-24 00:00:008-KStáhnout
2024-08-19 01:00:008-KStáhnout
2024-08-19 00:00:008-KStáhnout
2024-08-12 01:00:008-KStáhnout
2024-08-12 01:00:0010-QStáhnout
2024-08-12 00:00:008-KStáhnout
2024-08-12 00:00:0010-QStáhnout
2024-06-07 01:00:008-KStáhnout
2024-06-07 00:00:008-KStáhnout
2024-05-28 01:00:008-KStáhnout
2024-05-28 00:00:008-KStáhnout
2024-05-15 01:00:008-KStáhnout
2024-05-15 00:00:008-KStáhnout
2024-05-13 01:00:008-KStáhnout
2024-05-13 01:00:0010-QStáhnout
2024-05-13 00:00:008-KStáhnout
2024-05-13 00:00:0010-QStáhnout
2024-03-25 00:00:008-KStáhnout
2024-03-24 23:00:008-KStáhnout
2024-03-05 00:00:008-KStáhnout
2024-03-05 00:00:0010-KStáhnout
2024-03-04 23:00:008-KStáhnout
2024-03-04 23:00:0010-KStáhnout
2023-11-13 00:00:008-KStáhnout
2023-11-13 00:00:0010-QStáhnout
2023-11-12 23:00:008-KStáhnout
2023-11-12 23:00:0010-QStáhnout
2023-08-28 01:00:008-KStáhnout
2023-08-28 01:00:0010-QStáhnout
2023-08-28 00:00:008-KStáhnout
2023-08-28 00:00:0010-QStáhnout
2023-08-21 01:00:008-KStáhnout
2023-08-21 00:00:008-KStáhnout
2023-08-07 01:00:008-KStáhnout
2023-08-07 00:00:008-KStáhnout
preloader